Tubal choriocarcinoma presented as ruptured ectopic pregnancy: a case report and review of the literature

Shengjie Xu†, Xiaohong Song†, Chengjuan Jin* and Yanli Li*

Abstract

Background: Tubal choriocarcinoma is an extremely rare but highly malignant trophoblastic tumor, which may be either gestational or non-gestational in origin. Due to atypical clinical manifestations and symptoms similar to ectopic pregnancy, it is easily to be confused with ectopic pregnancy. In addition, inadequate understanding of this rare disease by clinicians often leads to misdiagnosis or missed diagnosis, which in turn results in delayed treatment or even tumor metastasis.

Case presentation: This report summarized a case of a woman who was finally diagnosed as tubal choriocarcinoma through the follow-up of serum β hCG levels and histopathological results after undergoing salpingectomy for being misdiagnosed as ectopic pregnancy. Five courses of adjuvant chemotherapy (5-fluorouracil, actinomycin-D, vinorelbine regime) have been administered to the patient in the prevention of any recurrences. During 1-year follow-up, the patient was asymptomatic and presented no evidence of recurrence.

Conclusions: Tubal choriocarcinoma is easily to be confused with ectopic pregnancy. By analyzing this case and previous related cases, we aimed to provide references for clinicians in the diagnosis and treatment of tubal choriocarcinoma.

Keywords: Tubal choriocarcinoma, Ectopic pregnancy, Histopathology, Immunohistochemistry, Chemotherapy

Background

Tubal choriocarcinoma is a kind of highly malignant trophoblastic tumor, which can be either gestational or non-gestational in origin. According to reports, the incidence of tubal choriocarcinoma is about 1.5/10⁶ [1]. The age of onset ranges from 16 to 56 years with an average of 33 years. Non-gestational tubal choriocarcinoma is extremely rare, and gestational tubal choriocarcinoma tends to occur on the basis of tubal pregnancy. In few cases, gestational tubal choriocarcinoma occurs after in vitro fertilization and fallopian tube sterilization, and even simultaneously with an intrauterine pregnancy [2].

Tubal choriocarcinoma can be easily misdiagnosed as ectopic pregnancy due to its main clinical manifestations similar to those of ectopic pregnancy, such as amenorrhea, irregular vaginal bleeding, abdominal pain, and elevated serum β hCG. Delayed treatment or even tumor metastasis may be caused if not diagnosed and intervened in time. Therefore, how to make a differential diagnosis and better understand and treat such diseases has attracted more and more attention from obstetricians and gynecologists in recent years. This article summarizes and analyzes the epidemiology, disease characteristics, clinical manifestations, diagnosis, and treatment of tubal choriocarcinoma that is easily
misdiagnosed as ectopic pregnancy, with a view to provide a reference for clinicians.

**Case presentation**

A 42-year-old Asian woman (gravida 5, para2) was admitted in the emergency room due to amenorrhea of 37 days, vaginal bleeding for 1 week, and intensive lower abdominal pain for half day. On examination, her vital functions were stable, blood pressure was 104/72 mmHg, and pulse rate was 83/min. Gynecological examination revealed a small amount of dark blood in the vagina and a sharp bilateral adnexal pain with rebound tenderness.

On laboratory examination, leukocyte count 14,880/mm³, hemoglobin 10.2 g/dl, and serum $\beta$-hCG $> 10,000$ mIU/ml were detected. CT scan revealed the presence of a low-density shadow in the left accessory area and a large amount of bloody effusions in the pelvic cavity (Fig. 1).

A woman of reproductive age (a history of abortion 13 months ago) presented with amenorrhea, vaginal bleeding, lower abdominal pain, and elevated serum $\beta$-hCG level raises the suspicion of ruptured ectopic pregnancy, which always presents with similar features and was considered as the first possibility in this case. Subsequently, approximately 3 ml non-coagulated blood was extracted from the puncture of posterior fornix of vagina. Considering that persistent bleeding may be life-threatening, a diagnostic laparoscopy was carried out immediately. Upon entering the abdominal cavity, blood clot of approximately 500 ml was seen and subsequently evacuated. The uterus was normal. The right fallopian tube and ovary were normal in appearance. The left ovary was within normal limits but there was a ruptured and actively bleeding ectopic mass of approximately 6 × 5 cm at the ampulla of left fallopian tube. A left-sided salpingectomy was carried out. Finally, the mass was sent for histopathological examination and the serum $\beta$ HCG levels were monitored continuously during postoperative period (Table 1).

Histopathological examination revealed that cytotrophoblasts and syncytiotrophoblasts were significantly proliferated in the mass, infiltrating the muscle layer of the fallopian tubal wall and the soft tissue of the adventitia, accompanied by extensive hemorrhage and necrosis (Fig. 2). Immunohistochemical analysis was positive for $\beta$ HCG, cytokeratin (CK), p63, p53, and $\alpha$-inhibin and negative for human placental lactogen (HPL), placental alkaline phosphatase (PLAP), PR, ER, PAX8, and WT1, whereas Ki 67 proliferation index was 60% (Fig. 3). The final diagnosis was tubal choriocarcinoma based on these findings.

Subsequently, a metastatic workup including CT scans of the brain, chest, and abdomen and contrast-enhanced MRI of the pelvis comprehensively ruled out the possibility of systemic metastasis of the tumor. Finally, the patient was categorized into FIGO stage I with WHO prognostic score of at least 10, representing high risk. Details of the prognostic scoring were shown as follows: age—score 1 (42 years of age), antecedent pregnancy—score 1 (abortion), interval from index pregnancy—score 4 (patient had an abortion ≥13 months back), pretreatment $\beta$ HCG value—score at least 2 (> 10,000 mIU/ml, no specific value), largest tumor size—score 2 (approximately 6 × 5 cm), site of metastasis—score 0 (none), number of metastatic lesions—score 0 (none), and previous failed chemotherapy—score 0 (none).

---

**Table 1** Monitoring of the serum $\beta$ hCG levels during perioperative stage

| Date                  | $\beta$ HCG (mIU/mL) | Note        |
|-----------------------|----------------------|-------------|
| Pre-operation         | > 10,000             | No exact value |
| Operation day         | > 10,000             | No exact value |
| 1st day after operation | 8152                | /           |
| 2nd day after operation | 5148                | /           |
| 10th day after operation | 570.9               | /           |
| 13th day after operation | 217.0               | /           |
| 14th day after operation | 127.7               | /           |
| 15th day after operation | 95.78               | /           |
| 21st day after operation | 2.1                 | FAV #1 start |

FAV 5-fluorouracil, actinomycin-D, vinorelbine
The serum β hCG level dropped to 95.78 mIU/ml at 15th day after operation and just before implementing adjuvant chemotherapy (5-fluorouracil, actinomycin-D, vinorelbine (FAV) regime). The normal level of β hCG was achieved after the first course of adjuvant chemotherapy (Table 1). Subsequently, four courses of consolidation chemotherapy in total were administered to the patient at intervals of 4 weeks in the prevention of any recurrences. The main adverse reactions during consolidation chemotherapy are bone marrow suppression and gastrointestinal. However, the toxicity and the side effects were tolerable after conventional symptomatic and supportive treatment.

In addition, the patient was advised to avoid pregnancy for 2 years and instructed to take effective contraceptive measures. During 1-year follow-up, the patient was asymptomatic and presented no evidence of recurrence. At present, the patient is still being followed up by performing serum β hCG testing and imaging examination at regular intervals.

Review of the literature
The available literatures of tubal choriocarcinoma presenting as ectopic pregnancy were obtained from MEDLINE and Google Scholar. Two scholars independently screened qualified publications from the database.
through the content of the title and abstract. A total of 12 cases were extracted from the databases, and the disease characteristics, clinical manifestations, treatment, and outcome of tubal choriocarcinoma were summarized in Table 2.

**Discussion**

Tubal choriocarcinoma is a rare but aggressive ectopic choriocarcinoma and may be either gestational or non-gestational in origin [14]. Regardless of gestational or non-gestational tubal choriocarcinoma, the common feature is that early metastasis and spread of the cancer are prone to occur, of which lung metastasis ranks the first place, followed by para-uterine metastasis [9, 12].

Patients with tubal choriocarcinoma are rare and often have similar clinical symptoms to those of tubal ectopic pregnancy including amenorrhea, vaginal bleeding, pelvic pain, and increased serum $\beta$ hCG [2, 15]. Therefore, diagnostic errors always occurred. In addition, the respiratory symptoms of advanced tubal choriocarcinoma patients with lung metastasis were often ignored, leading to delayed therapy and disease progression [9, 12]. Therefore, it is essential to exclude choriocarcinoma when diagnosing ectopic pregnancy, especially when patients are accompanied by respiratory distress, bloody sputum, and other respiratory symptoms.

It is important to distinguish between tubal choriocarcinoma and tubal ectopic pregnancy through dynamic monitoring of serum $\beta$ hCG levels, diagnostic laparoscopy, and histopathological examination. In general, the serum $\beta$ hCG of patients with tubal choriocarcinoma tended to abnormally elevate within a short time after amenorrhea, while that of patients with tubal ectopic pregnancy rarely exceeds 10,000 mIU/ml [14]. In some cases, the serum hCG levels of patients after surgery were not significantly reduced or even continuously increased. On this occasion, the tubal choriocarcinoma, even very rare, should be kept in mind. Diagnostic laparoscopy has a unique advantage in dealing with life-threatening intra-abdominal bleeding caused by either

| Author | Age | Clinical presentation | $\beta$ hCG (mIU/ml) | Tumor size (cm) | Surgery | Chemotherapy | Outcome |
|--------|-----|----------------------|----------------------|----------------|---------|--------------|---------|
| Mehrotra et al. [2] | 30 | Abdominal pain, fever, fatigue, tachycardia, and palpable mass 1 month after first trimester abortion | 326,100 | 14 × 16 | Left-sided salpingooophrectomy | EMA-CO | No evidence of recurrence |
| Mundkur et al. [3] | 26 | Mass abdomen, pain in the lower abdomen, vomiting, loss of weight, and loss of appetite | 151,545 | 10 × 10 × 5 | Right adnexectomy with partial infracholicomentectomy | EMA-CO | No evidence of recurrence |
| Rettenmaier et al. [4] | 32 | Abdominal cramping | 4759 | 3.5 × 1.7 × 2.8; 4.3 × 1.3 × 4.4 | Left-sided partial salpingectomy | Refused chemotherapy | Refused follow-up |
| Karaman et al. [5] | 31 | Amenorrhea, left lower abdominal pain, and fatigue | 29,251.4 | 4 × 3 | Left-sided complete salpingectomy | MTX | No evidence of recurrence |
| Cianci et al. [6] | 30 | Left lower abdominal pain | 24,474 | 8 | Left-sided salpingooophrectomy | EMA-CO | No evidence of recurrence |
| Boynukalin et al. [7] | 38 | Abdominal pain and vaginal bleeding | > 15,000 | None | Right-sided salpingectomy | None | None |
| Gálvez et al. [8] | 33 | Intense pain in the right iliac cavity and limited genital bleeding | 142.1 | 3.73 | Right-sided salpingectomy | VCR, ActD, MTX, LV | No evidence of recurrence |
| Lee et al. [9] | 31 | Dyspnea and blood-tinged sputum | 228,300 | 7 × 6 × 4 | Tomorectomy with left salpingectomy and infracolic omentectomy | EMA-CO | No evidence of recurrence |
| Butler et al. [10] | 24 | Vaginal bleeding, lower abdominal pain, and amenorrhea | 15,000 | 2.6 | Left-sided salpingectomy | MTX | No evidence of recurrence |
| Lin et al. [11] | 38 | Pregnancy of unknown location over 9 months following ovarian induction | 267,836 | 5 | Excision of the right ovarian cyst and the left uterine tube | MTX | No evidence of recurrence |
| Ibrahim et al. [12] | 34 | A positive urine test and respiratory distress | 752,601 | None | Left-sided salpingectomy and wedge resection of the broad ligament | None | Died of lung metastasis of tubal choriocarcinoma |
| Nakayama et al. [13] | 26 | Genital bleeding and a persistently high level of $\beta$ hCG | 9903 | 6.4 × 1.4 | Right-sided salpingectomy | None | No evidence of recurrence |

*EMA-CO* etoposide, methotrexate, actinomycin-D, cyclophosphamide, oncovin; *MTX* methotrexate; *ActD* actinomycin-D; *LV* leucovorin; *VCR* vincristine
ruptured ectopic pregnancy or tubal choriocarcinoma. Most importantly, histopathological specimens used for the final diagnosis could be obtained from diagnostic laparoscopy. In addition, it is essential to carefully dissect and inspect the excised lesions during the operation. When no villous structures are visually observed in the excised lesions, it is strongly recommended to execute intraoperative frozen section biopsy for the differential diagnosis between ectopic pregnancy and tubal choriocarcinoma. Histopathology is the golden standard for diagnosing choriocarcinoma. The typical histological characteristics of tubal choriocarcinoma are columns of hypervascular and poorly differentiated trophoblastic cells without villous structures and the invasion of muscular tissue with extensive hemorrhage and necrosis [2, 6].

Adjuvant chemotherapy following salpingectomy is essential and effective for the treatment of tubal choriocarcinoma. Currently, the chemotherapy regimens for tubal choriocarcinoma were selected with reference to the regimens used in the treatment of trophoblastic tumor. In general, patients of low-risk are treated with single-agent chemotherapy, while patients of high-risk are treated with combined chemotherapy. At present, the level of serum β hCG is widely used as the main criterion for judging the therapeutic effect of tubal choriocarcinoma. But even when the serum hCG reaches the normal level, consolidation chemotherapy is still recommended in prevention of clinical recurrences [2, 6, 14]. Generally, 1 to 2 courses of consolidation chemotherapy are recommended for low-risk patients and 2 to 4 courses for high-risk patients. Life-long serum β hCG monitoring and imaging examination is essential for patients with tubal choriocarcinoma as there is still no clear guideline indicating when to stop monitoring [16].

**Conclusion**

When diagnosing ectopic pregnancy, any other disease of tubal origin like tubal choriocarcinoma should be kept in mind for differential diagnosis. Careful examinations of pathologic specimens and postoperative monitoring of β hCG titers are emphasized to avoid misdiagnosis of ectopic tubal choriocarcinoma, although it is a rare condition. Apart from complete surgical resection, principles for the management of tubal choriocarcinoma also include postoperative adjuvant chemotherapy, imaging follow-up, and lifetime β hCG monitoring in order to avoid any risk of metastasis and recurrences.

**Abbreviations**

FAV: 5-Fluorouracil; actinomycin-D; vinorelbine; hCG: Human chorionic gonadotropin; CK: Cytokeratin; HPL: Human placental lactogen; PLAP: Placental alkaline phosphatase; EMA-CO: Etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine; MTX: Methotrexate; ActD: Actinomycin-D; LV: Leucovorin; VCR: Vincristine

**Acknowledgements**

Not applicable.

**Authors’ contributions**

S. Xu made substantial contributions to analysis and interpretation of data and was involved in drafting the manuscript and revising it critically for important intellectual content. X. Song made substantial contributions to conception, design and acquisition of data. C. Jin and Y. Li gave final approval of the version to be published and agreed to be accountable for all aspects of the work. The author(s) read and approved the final manuscript.

**Funding**

This work was supported financially by the National Natural Science Foundation of China (Grand No. 81302352) and the Natural Science Foundation of Shanghai (Grand No. 18ZR1430500).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The collection of patient’s clinical data was approved by the Ethics Committee of the School of Medicine of Shanghai Jiao Tong University and performed in accordance with the Declaration of Helsinki.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this report and accompanying images. A copy of this written consent is available for review by the Editor-in-Chief of this journal.

**Competing interests**

The authors declare that they have no competing interests.

**Received** 8 July 2020 Accepted: 3 September 2020

**Published online** 12 September 2020

**References**

1. Gillespie AM, Lidbury EA, Tidy JA, Hancock BWJ; JGC. The clinical presentation, treatment, and outcome of patients diagnosed with possible ectopic molar gestation. 2004;14:366-369.

2. Mihotza S, Singh U, Goel M, Chauhan S. Ectopic tubal choriocarcinoma: a rarity. BMJ Case Rep. 2012;2012:bcr-2012-006318.

3. Mundkur A, Rai L, Hebar S, Guvare S, Adiga P. Fallopian tube choriocarcinoma presenting as ovarian tumour: a case report. J Clin Diagn Res. 2015;9:QD1-2.

4. Rettenmaier MA, Khan HJ, Epstein HD, Nguyen D, Abaid LN, Goldstein BH. Gestational choriocarcinoma in the fallopian tube. J Obstet Gynecol. 2013; 33:912–4.

5. Karman E, Çetin O, Kolusari A, Bayram I. Primary tubal choriocarcinoma presented as ruptured ectopic pregnancy. J Clin Diagn Res. 2015;9:QD17-8.

6. Cianci S, Vitale SG, Tozzi R, Cignini P, Padula F, D’Emidio L, et al. Tubal primary metastatic choriocarcinoma coexistent with a viable early pregnancy: a case report. J Prenat Med. 2014;8:47–9.

7. Boyukalin PK, Erol Z, Aral AI, Boyar IH. Gestational choriocarcinoma arising in a tubal ectopic pregnancy: a case report. J Gynecol Oncol. 2011;32:592–3.

8. Gálvez CR, Fernández VC, de Los Reyes JM, Jaén MM, Teruel RG. Primary tubal choriocarcinoma. Int J Gynecol Cancer. 2013;23:33:912–4.

9. Lee SM, Kang JH, Oh SY, Hong JS, Kim JW. A successfully treated case of primary tubal choriocarcinoma coexistent with viable intrauterine pregnancy. Gynecol Oncol. 2005;97:671–3.

10. Butler R, Chadha Y, Davies J, Singh M. A case of primary tubal gestational choriocarcinoma. Aust N Z J Obstet Gynaecol. 2010;50:200–1.

11. Lin LH, Koji F, Azeka HE, Regina S, Manatha TL, Rosa MFA, et al. Gestational tubal choriocarcinoma presenting as a pregnancy of unknown location following ovarian induction. 2018;2018:1–6.

12. Ibraham, Zainal, Abidin, Lung, Wong, Song, et al. Fatal choriocarcinoma syndrome suspected of being an ectopic pregnancy. 2014.

13. Nakayama M, Namba A, Yasuda M, Hara M, Ishihara O, Ikura AJJO, et al. Gestational choriocarcinoma of fallopian tube diagnosed with a combination of p57. 2011;37(4):1493–6.
14. Nayama M, Lucot JP, Boukerrou M, Collinet P, Cosson M, Vinatier D. Tubal choriocarcinoma: a case report and review of the literature. J Gynecol Obstet Biol Reprod (Paris). 2007;36:83–6.

15. Muto MG, Lage JM, Berkowitz RS, Goldstein DP, Bernstein MR. Gestational trophoblastic disease of the fallopian tube. J Reprod Med. 1991;36:57–60.

16. Lin LH, Fushida K, Hase EA, Schultz R, Tenorio LM, Madia FAR, et al. Gestational tubal choriocarcinoma presenting as a pregnancy of unknown location following ovarian induction. Case Rep Obstet Gynecol. 2018;2018: 4705192.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.